🟡 Preliminary Evidence
BD (Becton, Dickinson and Company) has issued a voluntary nationwide recall of specific lots of BD® Intraosseous Vascular Access System Needle Sets, according to an FDA safety alert issued on 31 July 2026. The recall was initiated following user reports of difficulty removing the obturator—a critical safety issue that could compromise clinical outcomes during emergency vascular access procedures.
Key takeaways
- BD voluntarily recalled specific lots of intraosseous needle sets due to obturator removal difficulties
- The issue affects emergency medical procedures where rapid vascular access is critical
- Clinicians should verify product lot numbers and contact BD or the FDA for affected inventory
- This is a user-level recall, meaning it extends to healthcare facilities and emergency responders
What triggered the recall
The FDA announcement documents that users reported difficulty removing the obturator from BD® Intraosseous Vascular Access System Needle Sets in certain product lots. The obturator is a removable stylet that maintains needle sterility and protection during insertion; its removal is a necessary step before infusing medications or blood products through the intraosseous line. Difficulty in removal could delay critical resuscitation efforts or result in patient harm if the clinician applies excessive force.
Intraosseous vascular access—needle insertion directly into bone marrow—is a standard emergency procedure used when peripheral or central venous access cannot be rapidly achieved in critically ill or injured patients. Any device malfunction affecting this procedure is considered a quality and safety concern. BD initiated the recall at the user level, meaning affected product lots should be removed from circulation at all healthcare facilities and emergency medical services nationwide.
Immediate clinical actions for providers
Healthcare facilities, emergency departments, paramedic services, and other users of BD® Intraosseous Vascular Access System Needle Sets should verify their inventory against the specific lot numbers listed in the FDA safety alert. Affected lots must be quarantined and removed from clinical use immediately. Facilities should also review their intraosseous access protocols to ensure alternative vascular access equipment is available and staff are trained in backup procedures.
BD and the FDA’s Medical Devices division recommend that users report any adverse events related to this product to the FDA’s MedWatch programme. Clinicians who have used affected product lots and observed obturator removal difficulties should document the incident and report it through their facility’s quality and safety channels. This information helps the FDA monitor device performance and identify any additional safety signals.
Device safety and regulatory context
Intraosseous vascular access devices are classified as Class II medical devices under FDA regulations, requiring substantial evidence of safety and effectiveness before market clearance. Voluntary recalls of this type are triggered when manufacturers or users identify a defect that could affect device performance or patient safety. The fact that BD initiated this recall voluntarily, rather than waiting for FDA enforcement, reflects the company’s quality management response to user reports.
For clinical teams, this recall underscores the importance of maintaining current inventory management systems and staff training on alternative vascular access techniques. More broadly, it highlights how post-market surveillance—continuous monitoring of device performance after FDA clearance—plays a vital role in patient safety. Clinicians and facility managers should monitor Quality & Safety updates and the FDA’s MAUDE database for similar alerts affecting their emergency care protocols.
BD issued a user-level recall of specific intraosseous needle set lots due to obturator removal difficulties—a critical issue in emergency vascular access procedures where rapid device deployment is essential.
— FDA Safety Alert (31 July 2026)
What this means
Frequently asked questions
How do I know if my facility has affected product lots?
Check the specific lot numbers listed in the FDA safety alert. Compare these against your facility’s current inventory of BD® Intraosseous Vascular Access System Needle Sets. Contact BD directly or your medical device supplier if you are unsure whether you have affected lots in stock.
What should I do if I have already used a product from an affected lot?
If you or your team used a needle set from an affected lot and experienced obturator removal difficulty—or even if the procedure proceeded normally—report it to the FDA’s MedWatch programme and your facility’s quality department. This helps the FDA and BD understand the full scope of the defect and whether additional safety measures are needed.
Are there alternative intraosseous access products I should use instead?
Yes, other manufacturers produce intraosseous vascular access devices. Consult your facility’s procurement and clinical leadership to identify approved alternatives and ensure staff training on their use. Your emergency protocols should already include backup techniques and equipment for situations where specific devices are unavailable.
BD’s voluntary recall demonstrates the ongoing importance of device post-market surveillance and rapid clinical communication. Healthcare providers should use this as an opportunity to review emergency vascular access protocols, verify equipment inventory, and ensure all staff are trained in multiple access techniques. The Pharmacy & Prescribing section of GMJ News continues to track device safety alerts and recalls affecting clinical practice.
Was this article helpful?
Related Coverage
